Angiogenesis is crucial for many biological and pathological processes including the ovarian cycle and tumor growth. To identify molecules relevant for angiogenesis, we performed mRNA fingerprinting and subsequent Northern blot analysis using bovine cord-forming vs. monolayer-forming endothelial cells (EC) in vitro and staged bovine corpora lutea in vivo. We detected the receptor for activated C kinase 1 (RACK1), the specific receptor for activated protein kinase C ␤ (PKC␤), to be up-regulated in bovine cord-forming EC in vitro and in angiogenically active stages of bovine corpora lutea in vivo. Thereafter we established and determined the complete bovine RACK1 cDNA sequence. RACK1 was massively induced in subconfluent vs. contact-inhibited bovine EC, during angiogenesis in vitro, active phases of the murine ovarian cycle, human tumor angiogenesis, and in cancer cells in vivo as assessed by quantitative PCR and in situ hybridization. RACK1 transcripts were localized to proliferating EC in vitro and the endothelium of tumor neovascularizations in vivo by in situ hybridization. PKC␤ plays an important role in angiogenesis and cancer growth. Our data suggest that downstream signaling of PKC␤ in angiogenically active vs. inactive tissues and endothelium is affected by the availability of RACK1.-Berns, H., Humar, R., Hengerer, B., Kiefer, F. N., Battegay, E. J. RACK1 is up-regulated in angiogenesis and human carcinomas. FASEB J. 14, 2549 -2558 (2000)
Angiogenesis plays a pivotal role in many processes including embryonic development, myocardial ischemia, the ovarian cycle, and tumor growth (1) (2) (3) (4) (5) . To identify genes that are specifically up-or down-regulated in angiogenesis and thus may play a role in this process, we applied mRNA fingerprinting (differential display) to in vitro and in vivo models of angiogenesis and the corresponding quiescent endothelial cells and tissues. The model of angiogenesis in vitro consists of specific strains of cloned bovine aortic endothelial cells that spontaneously form capillary-like cords without addition of exogenous matrix substances (4, 6 -10) . In contrast, other strains of cloned bovine aortic endothelial cells form monolayers only (4, 6 -10) . These different strains thus represent different phenotypes of endothelium with a global shift in expressed genes. We and others have previously used this in vitro model to demonstrate that cord-forming endothelial cells show distinct responses to platelet-derived growth factor BB (PDGF-BB) (8, 11) , Transforming growth factor ␤ (10), and express specific angiogenesis-related patterns of extracellular matrices (4, 7, 12) . To ensure that in vitro findings correlate with angiogenesis in vivo (13) , we simultaneously applied mRNA fingerprinting to bovine corpora lutea classified to the early, mid, and late stages of the ovarian cycle. These stages represent active and regressive angiogenesis and served as an in vivo model of angiogenesis (5, 14 -16) .
Protein kinase C ␤ (PKC␤) plays an important role in angiogenesis (17, 18) . Here we report the isolation of the bovine receptor for PKC␤, i.e., the receptor for activated C kinase 1 (RACK1), which we found to be up-regulated in active angiogenesis. Bovine RACK1 cDNA was completely cloned and its nucleotide sequence determined. Expression studies revealed that RACK1 was distinctly up-regulated in angiogenesis in vitro and in vivo.
MATERIALS AND METHODS
Clones of bovine aortic endothelial cells (BAEC) were obtained from E. Helene Sage, University of Washington (Seattle). Several strains of cloned BAEC spontaneously forming cords without the addition of exogenous matrix substances or alternatively forming monolayers only were used (4, 6 -10, 12) .
Fresh bovine ovaries with corpora lutea were obtained at the local slaughterhouse. Pregnancy was excluded by macroscopic examination of uterine horns. Corpora lutea were dissected from the cortical tissue and classified by macroscopic appearance to three estrous cycle stages: early (days 2-4 of development), mid (days 5-17 of secretion), and late (days 18 -21 of regression) (14, 15) .
Mouse ovaries were staged by analysis of vaginal smears (19) and bought from BRL (Fü llinsdorf, Switzerland).
Human non-small cell lung, colon, and breast carcinomas were obtained from patients at the University Hospital, Basel, Switzerland, in accordance with regulations of the hospital ethics committee. All tissues were frozen in liquid nitrogen immediately after dissection and stored at Ϫ80°C.
Cell culture
Clones of BAEC were grown on uncoated plastic dishes (TPP, Trasadingen, Switzerland) in Dulbecco's modified Eagle's medium (Seromed, Berlin, Germany) supplemented with 10% (v/v) fetal bovine serum (Seromed), antibiotics-antimycotics (GibcoBRL, Merelbeke, Belgium), nonessential amino acids (Seromed), and 1 mM sodium pyruvate (Seromed) in a 37°C humidified atmosphere of 5% CO 2 . At 90% confluence, cells were trypsinized (Seromed) and split at a ratio of 1:3 until they were seeded on 15 cm dishes. Cells of the monolayer-forming BAEC clone were grown until contact inhibition and confluence as described before (7) . Cells of cordforming BAEC clones were grown 2 wk beyond confluence until a dense network of cord-like structures formed on top of the monolayers as described before (7).
mRNA fingerprinting and differential display
Differential display of messenger RNA by means of polymerase chain reaction (PCR) was carried out as described (20) with (dT) 12 CG as reverse anchored primer. Total RNA of tissues was extracted as described (21) . RNA quality was checked on a denaturing formaldehyde-agarose gel (Bio-Rad, Glattbrugg, Switzerland). First strand cDNA synthesis was carried out using the SuperScript Preamplification System (GibcoBRL), 5 g total RNA, RNAsin (Promega, Madison, Wis.), 200 M dNTPs, and 3.3 mol (dT) 12 CG (Intron Laboratory for Molecular Biology, Kaltbrunn, Switzerland). Generation and radioactive labeling of differently sized cDNA 3Ј-ends was facilitated by PCR and use of 1 l first strand cDNA reaction, 2.5 Ci [␣-32 P]dCTP (Amersham Pharmacia Biotech, Dü bendorf, Switzerland), 2 M dNTPs (Boehringer, Mannheim, Germany), 1.5 M (dT) 12 CG, and 1.5 M of 24 different decanucleotide forward primers (Intron) selected from a list of random sequences and tested for absence of self-complementarity of more than two nucleotides (22) . Amplification conditions were 94°C for 5 min, 40 cycles of 94°C for 1 min, 40°C for 1 min, and 72°C for 1 min, with the elongation time at the last cycle extended to 8 min. Two microliters PCR reaction per lane was fractionated on a denaturing 6% polyacrylamide gel (acrylamide-bisacrylamide ready-mix, GibcoBRL) containing 50% (w/v) urea (Sigma, Buchs, Switzerland) and 1 ϫ TBE. A gel was run at 1600 V for 1.5 h or 3 h and exposed to a MR-1 BioMax film (Kodak, Rochester, N.Y.) overnight.
Full-length cDNA cloning
Gel pieces corresponding to bands of interest were excised and cast into an agarose gel (Bio-Rad). cDNAs were transferred to activated DEAE cellulose membranes (Schleicher & Schuell, Feldbach, Switzerland) and eluted. Reamplification was carried out by PCR using 10 l cDNA dialysates, 20 M dNTPs, and the identical primers and amplification conditions of the differential PCR. Amplification products were separated on a 2% agarose gel (Bio-Rad), and DNA fragments of expected size were purified using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). Purified cDNA 3Ј-ends were ligated into the pGEM-T Vector (Promega) and transformed into Escherichia coli strain JM109 (Promega). Bacteria were selected on LB agar plates containing ampicillin (Sigma), IPTG (Promega), and X-Gal (Promega). White colonies were amplified for plasmid preparations using the QIAprep Spin Plasmid Kit (Qiagen). Double-strand sequencing was performed using the Sequenase DNA Sequencing Kit (Amersham) and [␣- 35 S]dATP (Amersham). Reaction products were separated on a denaturing 6% polyacrylamide gel (acrylamide-bisacrylamide ready-mix, GibcoBRL) containing 50% (w/v) urea (Sigma) and 0.5 ϫ TBE. A gel was run at 70 W for 2 h or 3 h and exposed to a MR-1 BioMax film (Kodak) overnight. Sequences were determined and matched against the DDBJ/EMBL/GenBank Nucleotide Sequence Database with the homology search program fastA.
The RACK1 cDNA 3Ј-clone was selected for full-length cloning using the 5Ј RACE System for Rapid Amplification of cDNA Ends (GibcoBRL) (23), 5 g total RNA of cordforming BAEC, and a RACK1 specific reverse primer (Microsynth, Balgach, Switzerland). The 5Ј RACE reaction product was ligated into the pGEM-T Vector, sequenced, and identified as RACK1 cDNA 5Ј-clone. Clones were combined and both full-length cDNA strands were sequenced (Microsynth).
Northern blot analysis
A RACK1 specific DIG-labeled antisense riboprobe was generated by in vitro transcription and use of 1 g linearized cDNA 3Ј-clone, the RiboMax RNA Production System (Promega), 7.5 mM rNTPs, and 750 M DIG-UTP (Boehringer). The probe was purified by gel filtration on a CentriSpin column (Princeton Separations, Adelphia, N.J.). Preparation of magnetic oligo (dT) particles has been described (24) . Poly (A) ϩ RNAs from tissues were purified using magnetic oligo (dT) particles as described (25) . Two micrograms of photometrically determined poly (A)
ϩ RNAs was glyoxalated in glyoxal solution (Fluka, Buchs, Switzerland) previously deionized with Resin AG 501-X8(D) (Bio-Rad), fractionated on a 1.2% agarose gel containing 10 mM sodium phosphate, transferred to an Electran nylon membrane (BDH, Poole, England), and cross-linked. Blots were hybridized with 200 ng RACK1 antisense riboprobe per ml DIG-EasyHyb hybridization solution (Boehringer) at 68°C overnight. 1.1 kb RACK1 transcripts were detected by chemoluminescence using DIG Wash & Block Buffer Set (Boehringer), alkaline phosphataseconjugated anti-DIG F ab fragments (Boehringer), and CDPStar (Promega). Blots were exposed to a MR-1 BioMax film (Kodak) for 10 min.
In situ hybridization
Immediately after resection, tissue samples were transferred into Tissue-Tek Cryomolds (Miles, Elkhart, Ind.), embedded with Tissue-Tek O.C.T. Compound (Sakura Finetek, Torrance, Calif.), and floated on isopentane cooled by solid CO 2 . Twelve micrometer slices were cut on a cryostat and transferred to silanized slides. Cells of BAEC clones were grown on culture slides (Nalge Nunc, Naperville, Ill.) under the conditions described (Cell culture section). Tissue sections and BAEC cultures were fixed in 4% paraformaldehyde (Merck, Dietikon, Switzerland) and acetylated in 0.25% acetic anhydride (Fluka). For hybridization, the RACK1 antisense riboprobe was used (Northern blot analysis section) and a RACK1 sense riboprobe as negative control. Aliquots of dilution series of sense and antisense riboprobes were spotted on a nylon membrane, cross-linked, and detected as described (see Northern blot Analysis) to serve for normalization of different anti-DIG F ab fragment binding affinities. Each slide was hybridized with normalized amounts of sense or antisense riboprobes in presence of 50% [w/v] formamide (Fluka) at 72°C overnight. Slides were processed using DIG Wash & Block Buffer Set (Boehringer), alkaline phosphatase-conjugated anti-DIG F ab fragments (Boehringer), and a substrate buffer containing NBT (Boehringer), BCIP (Sigma), and levamisole (Sigma). Development was carried out in the dark until a color reaction could be specifically observed on slides hybridized with the antisense riboprobe. Fluorescence counter staining of human endothelial cells was performed with FITC-conjugated lectin from Ulex europaeus (Sigma) (26) and of nuclei with Hoechst 33342 stain (Sigma). Slides were mounted with Aquamount Mountant (BDH) and photographed (Ektachrome 400ϫ film, Kodak).
Quantitative PCR

Poly (A)
ϩ or total RNAs from tissues were purified as described (25, 21) . First strand cDNA synthesis was carried out using the SuperScript Preamplification System (GibcoBRL), either 275 ng poly (A) ϩ RNA or 1-5 g total RNA, 500 M dNTPs, and 25 ng/l oligo(dT) [12] [13] [14] [15] [16] [17] [18] (GibcoBRL) . Real time quantitative PCR was performed on an Abi Prism 7700 machine and software (Perkin Elmer Biosystems, Foster City, Calif.). For each species, an optimal RACK1 amplicon, spanning the TaqMan probe (5Ј-FAM and 3Ј-TAMRA modified, Perkin Elmer, and Eurogentec, Seraing, Belgium) and two flanking primers (Microsynth), was identified by matching the criteria of the Primer Express software (Perkin Elmer). In 25 l reactions, 12.5 l master mix (Perkin Elmer), 8 pmol forward primer, 8 pmol reverse primer, and 16 pmol TaqMan probe were used. 40 cycle PCRs were performed in optical 96-well plates (Perkin Elmer) under standard conditions with threshold cycles C t set automatically. For absolute quantifications, a dilution series of 10 1 to 10 6 RACK1 plasmid copies served as standard curve.
Immunoblot analysis
Cells were lysed in 1ϫ SDS buffer (0.28 M Tris-Cl, pH 6.8, 45% glycerin, 0.1 M SDS) supplemented with a protease inhibitor mixture (Roche Molecular Biochemicals, Rotkreuz, Switzerland). Protein load was equalized by quantifying protein with the BCA Protein Assay Reagent (Pierce, Rockford, Ill.). Equal amounts of protein per lane were subjected to SDS-gel electrophoresis and electroblotting. Protein load was visualized by Amido Black staining (Sigma, Buchs, Switzerland). For detection, monoclonal IgM against RACK1 (Transduction Laboratories, San Diego, Calif.) and HRPO-conjugated IgG (Transduction Laboratories) were used to visualize RACK1 protein on BIOMAX films (Kodak) by a chemiluminescence reaction.
Statistical analysis
Differences between groups were analyzed with Mann-Whitney rank sum test or Kruskal-Wallis one way ANOVA on ranks. Results were expressed as box plots and considered statistically significant at *P Ͻ 0.05 and **P Ͻ 0.01.
RESULTS
RACK1 is induced in angiogenesis in vitro and in vivo
To identify genes differentially expressed in contactinhibited endothelial cells (EC) vs. EC engaged in angiogenesis, we applied a mRNA fingerprinting technique (20) to bovine in vitro and in vivo models of angiogenesis. Gene expression was analyzed by differential display in a confluent, contact-inhibited monolayer-forming clone of BAEC and in a cordforming BAEC clone at subconfluent, confluent, and cord-forming stages. Expression of a 357 bp cDNA, later identified as RACK1 (see below), was observed to increase with progressive stages of endothelial cord formation in cord-forming BAEC, whereas only limited expression was detected in the monolayerforming BAEC (Fig. 1a) . In parallel, differential gene expression was displayed in bovine corpora lutea of the early, mid, and late stages of the ovarian cycle that are associated with progressive, active, and regressive stages of angiogenesis in vivo. A moderate and strong expression of the same cDNA was present in corpora lutea of the early and mid stages, respectively, but no expression was found in the late-stage corpora lutea (Fig. 1a) . A close look at the autoradiographs revealed three bands that seem to be regulated in endothelial cells (Fig. 1a, left panel, second to fourth lane). Restriction analysis of six clones and sequencing of one clone of the three bands all proved to consist of RACK1 cDNA (see below). Thus, the three bands might be due to hybridizing of the 10 mer downstream primer with mismatches.
Northern blot analysis of the above-mentioned cells or tissues performed with a probe derived from the reamplified 357 bp cDNA confirmed differential expression of the cDNA. Angiogenically active tissues and cells proved to express substantially more of a 1.1 kb-sized mRNA than inactive cells or tissues both in vitro and in vivo (Fig. 1b) .
To ascertain up-regulation of RACK1 during angiogenesis in vitro, immunoblot analysis of RACK1 was performed in sequential stages of endothelial cord development (Fig. 1c) . Similar to RACK1 mRNA expression (Fig. 1a, left panel) , RACK1 protein expression was highest in confluent and cordforming stages of cord-forming BAEC as compared to subconfluent cord-forming BAEC (Fig. 1c) .
These experiments suggested a potential role for this cDNA in angiogenesis. We therefore proceeded to establish the full-length cDNA sequence and to identify this cDNA.
Bovine RACK1 full-length cDNA cloning
To identify the differentially expressed cDNA, fragments were extracted from the gel, reamplified, cloned, and sequenced. The clone proved to consist of homogenous DNA and had a length of 357 bp. Homology search identified the clone to be highly homologous to the 3Ј-end of RACK1 cDNA, and to include its stop codon and polyadenylation signal. This clone served as a template for full-length cDNA cloning using 5Ј RACE, as outlined in Materials and Methods. The derived full-length cDNA sequence from bovine tissue was determined on a length of 1091 nucleotides (Fig. 2) .
The bovine RACK1 cDNA has an open-reading frame of 951 nucleotides, coding for 317 amino acids. The coding region starts with the ATG start codon at nucleotide position 99 and ends with the TAA stop codon at nucleotide position 1050. The sequence of the isolated full-length cDNA clone was found to be 99% homologous from nucleotides 4 to 1091 to rat RACK1 cDNA (accession no. U03390) (27) , which is shown for comparison (Fig. 2) . There are eight mismatches within the 5Ј-and 3Ј-noncoding regions with a common length of 137 nucleotides, and three mismatches within the coding region with a length of 951 nucleotides, resulting in a 19-fold higher mismatch incidence in the noncoding regions. From these data, we concluded that we have isolated bovine RACK1 cDNA.
The bovine RACK1 cDNA shows also a high nucleotide sequence identity of 95% to mouse (accession no. D29802), 89% to human (accession no. M24194), and 82% to chicken (accession no. M24193) RACK1 cDNAs. The corresponding amino acid sequence identity is 100% to RACK1 of rat (accession no. A36986), mouse (accession no. I49700), human (accession no. P25388), and chicken (accession no. P25388) (not shown). These high degrees of homology imply an extremely high degree of conservation, which suggests that RACK1 may be essential for cellular functions (27) , possibly also in angiogenesis and endothelial proliferation.
RACK1 is up-regulated in subconfluent EC and angiogenesis in vitro
To investigate expression of RACK1 during endothelial proliferation, one of the most prominent aspects of angiogenesis (1, 2) , and angiogenesis in vitro, we assessed RACK1 mRNA expression by in situ hybridization and quantitative PCR. For this purpose, we again compared monolayer-forming and cord-forming BAEC clones during subconfluence and contact inhibition. RACK1 was ubiquitously expressed in cord-forming BAEC (Fig. 3c, subconfluent, and Fig.  3d , confluent, continuous growth; arrows, brown staining). Also, strong RACK1 mRNA expression was detected in subconfluent cultures of monolayerforming BAEC (Fig. 3a, b; arrows, brown staining).
Quantitative PCR was performed to better assess the changes occurring in contact-inhibited vs. prolif- erating monolayer-forming BAEC and in progressive stages of cord formation in cord-forming BAEC (Fig.  4) . During confluence, i.e., growth arrest, there was very little RACK1 expression in monolayer-forming BAEC. A 34-fold induction of RACK1 was observed in subconfluent, proliferating BAEC compared to growth-arrested monolayer-forming BAEC (Fig. 4) .
In cord-forming BAEC, RACK1 expression increased dramatically from subconfluence to stages where cords began forming (77,000-fold in confluent in comparison to subconfluent cord-forming endothelial cells) or formed (41,000,000-fold in cord-forming in comparison to subconfluent cordforming endothelial cells) (Fig. 4) . This latter increase of RACK1 expression during endothelial cord formation vastly exceeds the changes seen in rates of cell proliferation and does not necessarily reflect the rate of DNA synthesis (8) . Indeed, DNA synthesis in response to fetal calf serum, the conditions under which the cell cultures were harvested in this study, decreases continuously as the cells that differentiate into cords (8) . In contrast, the response of cells localized in cords to PDGF-BB increases as the cords form (8) . The massive increase in RACK1 expression during endothelial cord formation, also in comparison to proliferating monolayer-forming EC, therefore indicated an innate association of RACK1 expression with the changing phenotype of endothelial cells. However, increased expression was not specific for the cord-forming phenotype of endothelial cells because increased RACK1 expression could also be seen in subconfluent vs. confluent monolayer-form- Figure 2 . Bovine RACK1 cDNA is highly homologous to the already known rat cDNA nucleotide sequence. Shown are 1091 bovine RACK1 cDNA nucleotides comprising the complete coding region coding for 317 amino acids. The start and stop codons are underlined, the polyadenylation signal is in italics, and mismatches are in boldface. Bovine RACK1 cDNA is 99% homologous over 1088 nucleotides to the rat RACK1 cDNA displayed (accession no. U03390). The bovine sequence data are deposited in the DDBJ/EMBL/GenBank Nucleotide Sequence Database under the accession no. BTA132860. ing endothelial cells (Fig. 4) . The difference of RACK1 expression seen between subconfluent monolayer-vs. cord-forming clones in quantitative PCR (Fig. 4) was not detectable by in situ hybridization (Fig. 3a vs. 3c) .
Taken together, the data suggest that RACK1 can be associated with endothelial cord formation, i.e., angiogenesis in vitro.
RACK1 is expressed in cancer vessels and human carcinomas in vivo
Next we asked whether RACK1 might also be expressed in angiogenesis in vivo, e.g., in cancer. To assess RACK1 mRNA in different cell populations of human cancers in vivo, we performed RACK1 in situ hybridizations on human non-small cell lung and colon carcinomas. Endothelia (arrows) of a human non-small cell lung carcinoma (Fig. 5a, c) and human normal colon tissue (Fig. 5e) were specifically stained by fluorochrome-labeled Ulex europaeus agglutinin (yellow staining). RACK1 in situ hybridizations of adjacent slices were performed. The specific in situ signal is brownish representing weak expression and bluish reflecting a strong expression. Expression of RACK1 mRNA in the tumor endothelium of large ( Fig. 5d ; arrow, blue staining) and small vessels ( Fig. 5b ; arrow, blue staining) was detected. In contrast to large tumor vessels, expression of RACK1 mRNA seemed to be patchy in small vessels of non-small cell lung carcinomas, with some endothelial cells not staining at all (data not shown). In comparison to the endothelium of a normal colon mucosa vessel ( Fig. 5f ; arrow, brown staining), the RACK1 signal was stronger in the large vessel of a non-small cell lung carcinoma ( Fig. 5d ; arrow, blue staining). The difference in the strength of signals between control and tumor vessels was not obvious in small tumor vessels. A visible difference in the strength of the in situ signal was only present in the large vessels of the specific tumor samples investigated (Fig. 5d) vs. the normal control vessel (Fig. 5f) .
To better assess differences in RACK1 mRNA levels in human carcinomas in vivo, quantitative PCR was performed in human non-small cell lung, colon, and breast carcinomas in comparison to the patients' normal tissues. Compared with the patients' normal lung and colon tissues, RACK1 mRNA levels were found to be up-regulated 4.4-fold in human nonsmall cell lung carcinoma (Fig. 6a) and 18 .3-fold in human colon carcinoma (Fig. 6b) . RACK1 mRNA levels tended to be elevated in human breast carcinoma as compared to levels in the patients' normal breast tissues (Fig. 6c ), but to a lesser extent and without attaining statistical significance. From these observations we concluded that RACK1 is more strongly expressed in some cancers, including their vasculature, as compared with control tissues.
RACK1 is also associated with nonendothelial cells in angiogenically active tissues
We next asked whether RACK1 mRNA expression was exclusively localized to vessels in angiogenically active tissues in vivo. RACK1 in situ hybridizations were performed on slices of staged mouse ovaries representing the proestrus, estrus, and diestrus stages of the ovarian cycle. In this model, the estrus stage is known to be associated with high endothelial and nonendothelial rates of proliferation as compared to other stages of the ovarian cycle.
Strongest RACK1 mRNA expression was observed in follicles and follicular cells of the estrus stage ( Fig.  5g ; arrow, dark blue staining) as compared to other stages of the ovarian cycle (data not shown). These observations are consistent with our findings in bovine corpora lutea, and confirm that RACK1 expression occurs in active phases of the ovarian cycle that are known to be associated with angiogenesis in vivo. However, these experiments also show that RACK1 expression is associated with proliferation of nonendothelial cells such as follicular cells.
Similarly, substantial RACK1 mRNA expression was detected in epithelial cells of a human colon carcinoma ( Fig. 5h; arrow, brown staining) 
These data suggest that RACK1 expression is not only associated with active angiogenesis, but also with the activity of processes associated with angiogenesis.
DISCUSSION
Angiogenesis is associated with dramatic changes in expression of genes related to intracellular signal transduction (2) . We have performed mRNA fingerprinting to search for molecules up-or down-regulated in angiogenesis and found a massive up-regulation of the receptor for activated C kinase 1 (RACK1) in active angiogenesis in vivo and in vitro. However, expression of RACK1 was not particular to angiogenesis. Thus, we found RACK1 to be expressed in mouse follicles and human carcinoma cells in vivo, in normal human colon epithelial cells, and in endothelial cells not engaged in angiogenesis, albeit at lower levels.
RACK1 is a pivotal molecule directly associated with the signal transduction pathway of protein kinase C (PKC). Specifically, PKC␤, the ligand of RACK1, is known to play an important role in angiogenesis (17, 18) . Because PKC␤ requires RACK1 for signaling, our findings suggest the possibility of a specific and effective control for PKC␤ activities at the level of RACK1 expression, i.e., a control of angiogenesis associated endothelial processes at the level of the receptor for PKC␤, RACK1.
Our data clearly demonstrate that RACK1 is upregulated in different angiogenically active tissues in vitro and in vivo. In the monolayer-forming clone of bovine aortic endothelial cells (BAEC), a low RACK1 expression is associated with contact inhibition. In cord-forming BAEC, RACK1 expression increases dramatically during sequential stages of cord-formation, i.e., during angiogenesis in vitro. To corroborate these findings in tissues in vivo, we investigated RACK1 expression in tumor angiogenesis in vivo. RACK1 was up-regulated during tumor angiogenesis. Overall, levels of RACK1 expression were much higher in human non-small cell lung and colon carcinomas than in the corresponding normal tissues. Expression of RACK1 was not limited to the angiogenically active endothelium. It was also observed in colon cancer cells, normal colon mucosa, and ovarian follicles. Normal vessels and subconfluent monolayer-forming endothelial cells also expressed RACK1 mRNA, although to lesser levels than large tumor vessels or advanced stages of cordforming endothelial cells.
Taken together, the up-regulation of RACK1 in angiogenesis and in tissues associated with angiogenesis suggests a potential role for RACK1 in angiogenesis and processes associated with angiogenesis such as cancer. In view of the current knowledge of PKC␤ (see below), these results implicate that RACK1 may be important for the maintenance of tumor angiogenesis and tumor growth. To date, the PKC family consists of 12 different isozymes (28) . RACKs bind to activated PKC isozymes via a nonsubstrate binding site in a saturable and specific manner (29) . Each PKC isozyme is hypothesized to bind to its specific RACK upon activation. Thus, RACKs are activation-induced translocation targets for PKC isozymes and are located at various intracellular sites including plasma membranes, intra-and perinuclear structures, and cytoskeletal elements (29) . Hence, a given RACK would selectively direct its specific activated PKC isozyme to a subcellular compartment. RACKs may thus contribute to substrate specificity and selective function of its PKC isozyme (30) . RACK1 has been cloned as the first protein displaying the characteristics of RACKs and is a homologue of the ␤-subunit of heterotrimeric G-proteins (27) . The structure of RACK1 is composed of seven internal repeats forming a circular, propeller-like structure with seven blades (31, 32) . It belongs to the WD-repeat adaptor protein family known to regulate diverse cellular functions by simultaneously interacting with different classes of proteins (33) . RACK1 is likely to be essential for cellular functions because its amino acid sequence is 100% identical in human, rat, chicken (27) , mouse (34) , and (as we have shown here) cow.
RACK1 has been found to colocalize with activated PKC␤I and PKC␤II, suggesting specific binding of RACK1 to PKC␤ (35) , and was recently characterized as a shuttling protein that moves PKC␤II from one intracellular site to another (36) . PKC is a key enzyme involved in signal transduction for diverse cellular functions including growth, differentiation, and gene expression (37) , and has also been shown to play an important role in angiogenesis. The specific sites where activated PKC␤ resides either before or after being shuttled may define a specific substrate to be phosporylated, and thus a specific cellular feature to be induced. Hypothetically, increased shuttling of PKC␤II by up-regulation of RACK1 may result in increased phosphorylation of a near-by substrate that signals proliferation and angiogenesis and/or in decreased phosphorylation of a substrate that signals growth arrest or apoptosis. Thus, in addition to regulation of PKC␤ expression and activation, alterations in availability of RACK1 might be another important level at which PKC␤ signaling is controlled in angiogenesis and carcinogenesis.
PKC-activating phorbol esters induce angiogenesis in vitro and in vivo (38, 39) , and angiogenesis induced by cytokines or ethanol is PKC dependent (40, 41) . Signal transduction of VEGF, an important angiogenic molecule, has recently been shown to be PKC dependent in endothelial cells (42) . Specifically, the PKC␤I and PKC␤II isozymes, derived from alternative splicing of the same mRNA (43) , have been shown to be involved in angiogenesis. PKC␤I is one of two predominant PKC isozymes known to be present in BAEC; overexpression of PKC␤I in these cells promotes proliferation (44), a process crucial for angiogenesis. Activated PKC␤II translocates to different subcellular compartments of human microvascular endothelial cells on either phorbol ester vs. collagen treatment (17) . This difference in localization of PKC␤II after stimulation may be of functional relevance, i.e., explain why collagen treatment induces endothelial tube formation, whereas phorbol ester treatment induces a conversion of endothelial shape (17) . Obviously, both processes are necessary for angiogenesis (17, 1, 2) . Also, VEGF-induced tumor angiogenesis and tumor growth in vivo have recently been shown to be PKC␤ dependent (18) ; inhibition of PKC␤ significantly suppressed VEGFinduced neovacularizations in a mouse model of hepatocellular carcinoma cells (18) . PKC␤ inhibition reduced the size and number of VEGF-induced tumors both at initial stages of tumor development and after the tumors had attained a large size (18) . Taken together, these findings suggest that PKC␤I and PKC␤II, the specific ligands for RACK1, are crucial for angiogenesis. Our findings support the importance of PKC␤I and PKC␤II in angiogenesis and carcinogenesis, and suggest that their signaling may also be regulated at the level of their specific receptor RACK1. We speculate that the availability of RACK1 may be ratelimiting for the activities of PKC␤ whereby the amount of activated PKC␤II shuttled from one intracellular site to another may depend on the amount of RACK1 available. This speculation assumes that substantial expression of RACK1 is required for one or many RACK1-mediated processes to occur and that lower levels of RACK1 expression, which we observed in angiogenically inactive tissues or endothelial cells, are insufficient to mediate specific effects. It therefore remains to be clarified whether the differences in expression we observed translate into functional differences.
In conclusion, RACK1 was up-regulated during angiogenesis in vitro and in vivo, and was also expressed in tumor angiogenesis. RACK1 expression was higher in human non-small cell lung and colon carcinomas than in the corresponding normal tissues. RACK1 was also expressed in non-angiogenically active endothelia, although at lower levels, and nonendothelial components of angiogenically active or inactive tissues, i.e., ovarian follicles and colonic mucosa. In conjunction with data of other groups on PKC␤, these results suggest that RACK1 might contribute to angiogenesis and tumor growth. Future studies will address the mechanism of RACK1 gene regulation and the functional role of RACK1 in angiogenesis.
